Skip to main content

IMPACT-AD 2025 is now accepting applications!
Deadline to apply is April 30, 2025 at 5:00 PM PST.

Alzheimer’s Disease and Related Disorders (ADRD) are public health crises and critical areas of scientific effort. The National Institutes of Health, Alzheimer’s Association, and other federal, state, and non-profit funders of research are investing heavily in the science of ADRD in an effort to curb the impact of these debilitating, burdensome, and costly disorders. Tremendous advances made in understanding the pathobiology of disease will ultimately have one final pathway to impacting clinical care and public health – randomized controlled clinical trials.

IMPACT-AD was founded to train the next generation of ADRD clinical trialists, to ensure that investments in discovery yield outcomes for patients and families. Our goal is to provide education and tools to establish a national cohort of qualified investigators to guide the field toward improved therapies. Equally importantly, we are focused on diversifying the ADRD trial workforce. This diversity is manifold: it includes the demographic characteristics of investigators (age, race, ethnicity, etc.), but also their specialties (physicians, psychologists, statisticians, etc.), backgrounds (rural, urban, etc.), and career stage or current position (current AD Clinical Trial Consortium (ACTC) site, non-ACTC academic site, non-academic site). IMPACT-AD will be successful if it produces an outstanding, well-trained, diverse, and knowledgeable cohort of collaborative investigators who will carry the mantle of the National Plan to Address AD.

IMPACT-AD will leverage the outstanding collection of investigators, including members of the ACTC and beyond. National and international leaders in ADRD trials will gather annually to provide a unique, interactive, cutting edge educational experience in ADRD trials. We offer two tracks for those interested in advancing their careers in ADRD trials.

Two unique in-person tracks will be offered as part of IMPACT-AD. Tracks will commence simultaneously and overlap. Please read the eligibility criteria for each track carefully and ensure your qualifications align appropriately. 

Professionals Track (3.5 days)
This track seeks applications from individuals with at least 2 years of experience in AD/ADRD research and/or clinical trials who wish to further their knowledge and advance their careers in AD/ADRD trials. Applicants may currently serve in a broad variety of roles, including but not limited to clinicians, study coordinators, statisticians, psychometricians, and other study professionals.

Fellowship Track (5 days)
This track seeks applications from individuals seeking to serve as Principal Investigators in AD/ADRD trials now or in the future, and offers mentored training in protocol development. Applications are open to individuals in their fellowship or postdoctoral training, faculty members or equivalent positions.

Participation is competitive and open to individuals with a full-time position at their respective institution within the United States. Applicants are permitted to apply to only one track per application cycle. 

Participation in the Global Pilot Program: If your place of residence and primary appointment are outside of the United States, you might be eligible for our global pilot program. If interested, please email your CV/Biosketch and a Letter of Support to our IMPACT-AD Program Email Address, and include “IMPACT-AD 2025 Global Eligibility” in the subject of your email. Your materials will be reviewed, and you will be notified regarding your eligibility to apply. Please do not submit an application in ProposalCentral unless your eligibility has been reviewed via this mechanism. If you do not receive a response within 14 days, please resend your materials.

All submission templates and instructions are located in the Course Details tab of this website. If you have any questions regarding the application or the IMPACT-AD Course, contact us here. Good luck on your application!

IMPACT-AD

Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD

A comprehensive training program in clinical trials for Alzheimer’s disease and related dementias.

San Diego, CA
Professionals Track: August 24 – August 27, 2025
Fellowship Track: August 24 – August 29, 2025

Welcome to IMPACT-AD

Thank you for your interest in the IMPACT-AD Course.

Read a welcome letter from the IMPACT-AD Co-Directors

Alzheimer’s Disease and Related Disorders (ADRD) are public health crises and critical areas of scientific effort. The National Institutes of Health, Alzheimer’s Association, and other federal, state, and non-profit funders of research are investing heavily in the science of AD/ADRD in an effort to curb the impact of these debilitating, burdensome, and costly disorders. Tremendous advances made in understanding the pathobiology of disease will ultimately have one final pathway to impacting clinical care and public health – randomized controlled clinical trials.

IMPACT-AD was founded to train the next generation of AD/ADRD clinical trialists, to ensure that investments in discovery yield outcomes for patients and families. Our goal is to provide education and tools to establish a national cohort of qualified investigators to guide the field toward improved therapies. Equally importantly, we are focused on diversifying the AD/ADRD trial workforce. This diversity is manifold: it includes the demographic characteristics of investigators (age, race, ethnicity, etc.), but also their specialties (physicians, psychologists, statisticians, etc.), backgrounds (rural, urban, etc.), and career stage or current position (current AD Clinical Trial Consortium (ACTC) site, non-ACTC academic site, non-academic site). IMPACT-AD will be successful if it produces an outstanding, well-trained, diverse, and knowledgeable cohort of collaborative investigators who will carry the mantle of the National Plan to Address AD.

IMPACT-AD will leverage the outstanding collection of investigators, including members of the ACTC and beyond. National and international leaders in AD/ADRD trials will gather annually to provide a unique, interactive, cutting-edge educational experience in AD/ADRD trials. We offer two tracks for those interested in advancing their careers in ADRD trials.

Sincerely,

Rema Raman, PhD

IMPACT-AD Co-Director

Joshua Grill, PhD

IMPACT-AD Co-Director

Watch a message from Richard J. Hodes, MD, Director of the National Institute on Aging

A message from Maria Carrillo, PhD, CSO of the Alzheimer’s Association

Course Tracks

Professionals Track:
August 24 - August 27, 2025

Individuals selected to this track have at least 2 years of experience in ADRD research and/or clinical trials (in a broad variety of roles including, but not limited to clinicians, study coordinators, psychometricians, and other study professionals) and will be trained to further their knowledge and advance their careers in ADRD trials.

Fellowship Track:
August 24 - August 29, 2025

Individuals selected to this track will be trained to serve as Principal Investigators in ADRD trials and offered mentored training in protocol development.

Course Details

Goals of the Course

To provide early-stage investigators and those new to AD trials with a unique, comprehensive, and active learning experience in ADRD trials.

This will be accomplished by leveraging the full infrastructure and expertise of the Alzheimer’s Clinical Trials Consortium (ACTC) to enable a diverse range of clinicians, scientists and researchers to receive modern and robust training on ADRD clinical trials.

IMPACT-AD is an Alzheimer’s Disease and related disorders (ADRD) course that aims to educate and promote diversity among research professionals and future principal investigators in the field of ADRD research.

  • Lectures will be given by national leaders in ADRD trials, and attendees will have the opportunity to work closely with the field’s top investigators in small group workshops.
  • IMPACT-AD emphasizes diversity of trainees, interactive learning, a cooperative culture among alumni and long-term metrics of success.
  • The course will be free to those who attend and will count as CME credit.
More Info

Our Supporters

National Institute on Aging
Alzheimer's Association
Alzheimer's Clinical Trials Consortium
UCI MIND
USC ATRI

Partners